|
1.
|
Kishko M, Somasundaran M, Brewster F, Sullivan JL, Clapham PR, Luzuriaga K. Genotypic and functional properties of early infant HIV-1 envelopes. Retrovirology. 2011; 8:67.
|
|
|
|
|
2.
|
Clute SC, Naumov YN, Watkin LB, Aslan N, Sullivan JL, Thorley-Lawson DA, Luzuriaga K, Welsh RM, Puzone R, Celada F, Selin LK. Broad cross-reactive TCR repertoires recognizing dissimilar epstein-barr and influenza A virus epitopes. J Immunol. 2010 Dec 1; 185(11):6753-64.
|
|
|
|
|
3.
|
Serur D, Saal S, Wang J, Sullivan J, Bologa R, Hartono C, Dadhania D, Lee J, Gerber LM, Goldstein M, Kapur S, Stubenbord W, Belenkaya R, Marin M, Seshan S, Ni Q, Levine D, Parker T, Stenzel K, Smith B, Riggio R, Cheigh J. Deceased-donor kidney transplantation: improvement in long-term survival. Nephrol Dial Transplant. 2011 Jan; 26(1):317-24.
|
|
|
|
|
4.
|
Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010 May 27; 362(21):1993-2000.
|
|
|
|
|
5.
|
Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15; 201(6):803-13.
|
|
|
|
|
6.
|
Mehta N, Trzmielina S, Nonyane BA, Eliot MN, Lin R, Foulkes AS, McNeal K, Ammann A, Eulalievyolo V, Sullivan JL, Luzuriaga K, Somasundaran M. Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR. PLoS One. 2009; 4(6):e5819.
|
|
|
|
|
7.
|
Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, van der Ryst E, Mayer H. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis. 2009 Jun 1; 199(11):1638-47.
|
|
|
|
|
8.
|
Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, Barker P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine. 2008 Dec 9; 26(52):6883-93.
|
|
|
|
|
9.
|
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 Oct 2; 359(14):1429-41.
|
|
|
|
|
10.
|
Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood. 2008 Feb 1; 111(3):1420-7.
|
|
|
|
|
11.
|
Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Influence of EBV on the peripheral blood memory B cell compartment. J Immunol. 2007 Sep 1; 179(5):3153-60.
|
|
|
|
|
12.
|
Newell ML, Huang S, Fiore S, Thorne C, Mandelbrot L, Sullivan JL, Maupin R, Delke I, Watts DH, Gelber RD, Cunningham CK. Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infect Dis. 2007; 7:60.
|
|
|
|
|
13.
|
Verity EE, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer DE, Cunningham A, Learmont J, Dyer W, Sullivan J, Churchill M, Wesselingh SL, Gabuzda D, Gorry PR, McPhee DA. Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions. J Virol. 2007 Sep; 81(17):9268-78.
|
|
|
|
|
14.
|
Wang YM, Dyer WB, Workman C, Wang B, Peng NK, Lachireddy K, Chew CB, Sullivan J, Saksena NK. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res. 2007 Mar; 5(2):235-50.
|
|
|
|
|
15.
|
Luzuriaga K, Newell ML, Dabis F, Excler JL, Sullivan JL. Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet. 2006 Aug 5; 368(9534):511-21.
|
|
|
|
|
16.
|
Rosario MC, Poland B, Sullivan J, Westby M, van der Ryst E. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr. 2006 Jun; 42(2):183-91.
|
|
|
|
|
17.
|
Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan JL, Zaki S, Subbarao K, Ambrosino DM. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis. 2006 Mar 1; 193(5):685-92.
|
|
|
|
|
18.
|
Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A. 2005 Dec 13; 102(50):18093-8.
|
|
|
|
|
19.
|
Clute SC, Watkin LB, Cornberg M, Naumov YN, Sullivan JL, Luzuriaga K, Welsh RM, Selin LK. Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest. 2005 Dec; 115(12):3602-12.
|
|
|
|
|
20.
|
Greenough TC, Carville A, Coderre J, Somasundaran M, Sullivan JL, Luzuriaga K, Mansfield K. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am J Pathol. 2005 Aug; 167(2):455-63.
|
|
|
|
|
21.
|
Huang DD, Bremer JW, Brambilla DJ, Palumbo PE, Aldrovandi G, Eshleman S, Brown C, Fiscus S, Frenkel L, Hamdan H, Hart S, Kovacs A, Krogstad P, LaRussa P, Sullivan J, Weinberg A, Zhao YQ. Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays. J Clin Microbiol. 2005 Aug; 43(8):3963-70.
|
|
|
|
|
22.
|
Farrow MA, Somasundaran M, Zhang C, Gabuzda D, Sullivan JL, Greenough TC. Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation. AIDS Res Hum Retroviruses. 2005 Jun; 21(6):565-74.
|
|
|
|
|
23.
|
Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis. 2005 Feb 15; 191(4):507-14.
|
|
|
|
|
24.
|
Luzuriaga K, Sullivan JL. Prevention of mother-to-child transmission of HIV infection. Clin Infect Dis. 2005 Feb 1; 40(3):466-7.
|
|
|
|
|
25.
|
Li W, Greenough TC, Moore MJ, Vasilieva N, Somasundaran M, Sullivan JL, Farzan M, Choe H. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J Virol. 2004 Oct; 78(20):11429-33.
|
|
|
|
|
26.
|
Cunningham CK, Balasubramanian R, Delke I, Maupin R, Mofenson L, Dorenbaum A, Sullivan JL, Gonzalez-Garcia A, Thorpe E, Rathore M, Gelber RD. The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. J Acquir Immune Defic Syndr. 2004 Jul 1; 36(3):800-7.
|
|
|
|
|
27.
|
Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004 Jun 10; 350(24):2471-80.
|
|
|
|
|
28.
|
Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol. 2004 May; 78(10):5194-204.
|
|
|
|
|
29.
|
Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A. 2004 Jan 6; 101(1):239-44.
|
|
|
|
|
30.
|
Hiebenthal-Millow K, Greenough TC, Bretttler DB, Schindler M, Wildum S, Sullivan JL, Kirchhoff F. Alterations in HIV-1 LTR promoter activity during AIDS progression. Virology. 2003 Dec 5; 317(1):109-18.
|
|
|
|
|
31.
|
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003 Nov 27; 426(6965):450-4.
|
|
|
|
|
32.
|
Sullivan JL. Prevention of mother-to-child transmission of HIV--what next? J Acquir Immune Defic Syndr. 2003 Sep; 34 Suppl 1:S67-72.
|
|
|
|
|
33.
|
Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, Culnane M, Sullivan JL. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003 Jun 1; 33(2):153-6.
|
|
|
|
|
34.
|
Brambilla D, Jennings C, Aldrovandi G, Bremer J, Comeau AM, Cassol SA, Dickover R, Jackson JB, Pitt J, Sullivan JL, Butcher A, Grosso L, Reichelderfer P, Fiscus SA. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol. 2003 May; 41(5):1888-93.
|
|
|
|
|
35.
|
Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd Jr RM, Reid C, Morgan GF, Winslow DL. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol. 2003 Apr; 41(4):1586-93.
|
|
|
|
|
36.
|
Precopio ML, Sullivan JL, Willard C, Somasundaran M, Luzuriaga K. Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J Immunol. 2003 Mar 1; 170(5):2590-8.
|
|
|
|
|
37.
|
Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, Nikodem C, Hall D, Gigliotti M, Robinson P, Boshoff L, Sullivan JL. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003 Mar 1; 187(5):725-35.
|
|
|
|
|
38.
|
Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002 Sep; 21(9):835-8.
|
|
|
|
|
39.
|
Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002 Jul 10; 288(2):189-98.
|
|
|
|
|
40.
|
Somasundaran M, Sharkey M, Brichacek B, Luzuriaga K, Emerman M, Sullivan JL, Stevenson M. Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A. 2002 Jul 9; 99(14):9503-8.
|
|
|
|
|
41.
|
Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002 Jul 15; 186(2):181-8.
|
|
|
|
|
42.
|
Haran JP, Greenough TC, Luzuriaga K, Sullivan JL, Flanigan T, Somasundaran M. Enhanced culture method for detection of replication-competent virus in peripheral blood mononuclear cells of HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 2002 May 20; 18(8):577-83.
|
|
|
|
|
43.
|
Catalina MD, Sullivan JL, Brody RM, Luzuriaga K. Phenotypic and functional heterogeneity of EBV epitope-specific CD8+ T cells. J Immunol. 2002 Apr 15; 168(8):4184-91.
|
|
|
|
|
44.
|
Luzuriaga K, Sullivan JL. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev. 2002 Jan-Mar; 4(1):21-6.
|
|
|
|
|
45.
|
Scott ZA, Chadwick EG, Gibson LL, Catalina MD, McManus MM, Yogev R, Palumbo P, Sullivan JL, Britto P, Gay H, Luzuriaga K. Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol. 2001 Dec 15; 167(12):7134-40.
|
|
|
|
|
46.
|
Catalina MD, Sullivan JL, Bak KR, Luzuriaga K. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol. 2001 Oct 15; 167(8):4450-7.
|
|
|
|
|
47.
|
Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenson M, Sullivan JL. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol. 2000 Aug; 74(15):6984-91.
|
|
|
|
|
48.
|
Wagar EJ, Cromwell MA, Shultz LD, Woda BA, Sullivan JL, Hesselton RM, Greiner DL. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol. 2000 Jul 1; 165(1):518-27.
|
|
|
|
|
49.
|
Luzuriaga K, Sullivan JL. Viral and immunopathogenesis of vertical HIV-1 infection. Pediatr Clin North Am. 2000 Feb; 47(1):65-78.
|
|
|
|
|
50.
|
Forte SE, Somasundaran M, Sullivan JL. Attenuation of human immunodeficiency virus type 1 cytopathic effects by replacing a 424-bp region of envelope from a noncytopathic biological clone. AIDS Res Hum Retroviruses. 2000 Jan 20; 16(2):125-37.
|
|
|
|
|
51.
|
Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 2000 Jan; 6(1):76-81.
|
|
|
|
|
52.
|
Greenough TC, Brettler DB, Kirchhoff F, Alexander L, Desrosiers RC, O'Brien SJ, Somasundaran M, Luzuriaga K, Sullivan JL. Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort. J Infect Dis. 1999 Dec; 180(6):1790-802.
|
|
|
|
|
53.
|
Sullivan JL. The abnormal gene in X-linked lymphoproliferative syndrome. Curr Opin Immunol. 1999 Aug; 11(4):431-4.
|
|
|
|
|
54.
|
Luzuriaga K, Wu H, McManus M, Britto P, Borkowsky W, Burchett S, Smith B, Mofenson L, Sullivan JL. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol. 1999 Jan; 73(1):362-7.
|
|
|
|
|
55.
|
Luzuriaga K, Sullivan JL. Prevention and treatment of pediatric HIV infection. JAMA. 1998 Jul 1; 280(1):17-8.
|
|
|
|
|
56.
|
Berger C, McQuain C, Sullivan JL, Nadal D, Quesenberry PJ, Knecht H. The 30-bp deletion variant of Epstein-Barr virus-encoded latent membrane protein-1 prevails in acute infectious mononucleosis. J Infect Dis. 1997 Nov; 176(5):1370-3.
|
|
|
|
|
57.
|
Pal A, Greenough TC, Sullivan JL, Somasundaran M. In vitro characterization of adult primary human immunodeficiency virus type 1: demonstration of distinctive single-cell killing phenotypes in spite of similar levels of viral replication. J Infect Dis. 1997 Oct; 176(4):933-40.
|
|
|
|
|
58.
|
Pugatch D, Sullivan JL, Pikora CA, Luzuriaga K. Delayed generation of antibodies mediating human immunodeficiency virus type 1-specific antibody-dependent cellular cytotoxicity in vertically infected infants. WITS Study Group. Women and Infants Transmission Study. J Infect Dis. 1997 Sep; 176(3):643-8.
|
|
|
|
|
59.
|
Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis. 1997 Jul; 176(1):118-25.
|
|
|
|
|
60.
|
Tamaki H, Byron KS, Sullivan JL, Somasundaran M. Detection and differentiation of Epstein-Barr virus strains by in situ polymerase chain reaction. Mol Cell Probes. 1997 Jun; 11(3):237-41.
|
|
|
|
|
61.
|
Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, Cort S, Sullivan JL. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 1997 May 8; 336(19):1343-9.
|
|
|
|
|
62.
|
Pikora CA, Sullivan JL, Panicali D, Luzuriaga K. Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med. 1997 Apr 7; 185(7):1153-61.
|
|
|
|
|
63.
|
Forte SE, Sullivan JL, Somasundaran M. In vitro characterization of HIV type 1 biological clones from asymptomatic and symptomatic pediatric patients. AIDS Res Hum Retroviruses. 1996 Nov 20; 12(17):1585-93.
|
|
|
|
|
64.
|
Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, Lamson M, Cort S, Sullivan JL. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis. 1996 Oct; 174(4):713-21.
|
|
|
|
|
65.
|
Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL, Shultz LD. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis. 1995 Oct; 172(4):974-82.
|
|
|
|
|
66.
|
Tamaki H, Beaulieu BL, Somasundaran M, Sullivan JL. Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses to Epstein-Barr virus in children. J Infect Dis. 1995 Sep; 172(3):739-46.
|
|
|
|
|
67.
|
Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1; 8(2):141-51.
|
|
|
|
|
68.
|
Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol. 1995 Jan 1; 154(1):433-43.
|
|
|
|
|
69.
|
Forte SE, Byron KS, Sullivan JL, Somasundaran M. Non-syncytium-inducing HIV type 1 isolated from infected individuals replicates in MT-2 cells. AIDS Res Hum Retroviruses. 1994 Dec; 10(12):1613-8.
|
|
|
|
|
70.
|
Somasundaran M, Zapp ML, Beattie LK, Pang L, Byron KS, Bassell GJ, Sullivan JL, Singer RH. Localization of HIV RNA in mitochondria of infected cells: potential role in cytopathogenicity. J Cell Biol. 1994 Sep; 126(6):1353-60.
|
|
|
|
|
71.
|
Greenough TC, Somasundaran M, Brettler DB, Hesselton RM, Alimenti A, Kirchhoff F, Panicali D, Sullivan JL. Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 1994 Apr; 10(4):395-403.
|
|
|
|
|
72.
|
Luzuriaga K, Sullivan JL. Pathogenesis of vertical HIV-1 infection: implications for intervention and management. Pediatr Ann. 1994 Mar; 23(3):159-66.
|
|
|
|
|
73.
|
Durbin WA, Sullivan JL. Epstein-Barr virus infection. Pediatr Rev. 1994 Feb; 15(2):63-8; quiz 68.
|
|
|
|
|
74.
|
Hesselton RM, Koup RA, Cromwell MA, Graham BS, Johns M, Sullivan JL. Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution. J Infect Dis. 1993 Sep; 168(3):630-40.
|
|
|
|
|
75.
|
Koup RA, Brewster F, Grob P, Sullivan JL. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. AIDS. 1993 Sep; 7(9):1181-4.
|
|
|
|
|
76.
|
Luzuriaga K, McQuilken P, Alimenti A, Somasundaran M, Hesselton R, Sullivan JL. Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis. 1993 May; 167(5):1008-13.
|
|
|
|
|
77.
|
Woda BA, Sullivan JL. Reactive histiocytic disorders. Am J Clin Pathol. 1993 Apr; 99(4):459-63.
|
|
|
|
|
78.
|
Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother. 1993 Feb; 37(2):178-82.
|
|
|
|
|
79.
|
Alimenti A, O'Neill M, Sullivan JL, Luzuriaga K. Diagnosis of vertical human immunodeficiency virus type 1 infection by whole blood culture. J Infect Dis. 1992 Nov; 166(5):1146-8.
|
|
|
|
|
80.
|
Brettler DB, Somasundaran M, Forsberg AF, Krause E, Sullivan JL. Silent human immunodeficiency virus type 1 infection: a rare occurrence in a high-risk heterosexual population. Blood. 1992 Nov 1; 80(9):2396-400.
|
|
|
|
|
81.
|
Koup RA, Pikora CA, Luzuriaga K, Brettler DB, Day ES, Mazzara GP, Sullivan JL. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J Exp Med. 1991 Dec 1; 174(6):1593-600.
|
|
|
|
|
82.
|
Koup RA, Robinson JE, Nguyen QV, Pikora CA, Blais B, Roskey A, Panicali D, Sullivan JL. Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS. 1991 Nov; 5(11):1309-14.
|
|
|
|
|
83.
|
Alimenti A, Luzuriaga K, Stechenberg B, Sullivan JL. Quantitation of human immunodeficiency virus in vertically infected infants and children. J Pediatr. 1991 Aug; 119(2):225-9.
|
|
|
|
|
84.
|
Luzuriaga K, Koup RA, Pikora CA, Brettler DB, Sullivan JL. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr. 1991 Aug; 119(2):230-6.
|
|
|
|
|
85.
|
Koup RA, Merluzzi VJ, Hargrave KD, Adams J, Grozinger K, Eckner RJ, Sullivan JL. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis. 1991 May; 163(5):966-70.
|
|
|
|
|
86.
|
Koup RA, Pikora CA, Mazzara G, Panicali D, Sullivan JL. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol. 1991; 4(4):215-23.
|
|
|
|
|
87.
|
Yang WC, Hesselton RM, Sullivan JL. Immune responses to Herpesvirus sylvilagus infection in cottontail rabbits. J Immunol. 1990 Sep 15; 145(6):1929-33.
|
|
|
|
|
88.
|
Lawrence JB, Marselle LM, Byron KS, Johnson CV, Sullivan JL, Singer RH. Subcellular localization of low-abundance human immunodeficiency virus nucleic acid sequences visualized by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1990 Jul; 87(14):5420-4.
|
|
|
|
|
89.
|
Singer RH, Byron KS, Lawrence JB, Sullivan JL. Detection of HIV-1-infected cells from patients using nonisotopic in situ hybridization. Blood. 1989 Nov 1; 74(6):2295-301.
|
|
|
|
|
90.
|
Tomkinson BE, Maziarz R, Sullivan JL. Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol. 1989 Jul 15; 143(2):660-70.
|
|
|
|
|
91.
|
Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies. Blood. 1989 May 15; 73(7):1859-63.
|
|
|
|
|
92.
|
Koup RA, Sullivan JL, Levine PH, Brettler D, Mahr A, Mazzara G, McKenzie S, Panicali D. Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood. 1989 May 15; 73(7):1909-14.
|
|
|
|
|
93.
|
Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL. Soluble CD8 during T cell activation. J Immunol. 1989 Apr 1; 142(7):2230-6.
|
|
|
|
|
94.
|
Koup RA, Sullivan JL, Levine PH, Brewster F, Mahr A, Mazzara G, McKenzie S, Panicali D. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol. 1989 Feb; 63(2):584-90.
|
|
|
|
|
95.
|
Medveczky MM, Geck P, Clarke C, Byrnes J, Sullivan JL, Medveczky PG. Arrangement of repetitive sequences in the genome of herpesvirus Sylvilagus. J Virol. 1989 Feb; 63(2):1010-4.
|
|
|
|
|
96.
|
Koup RA, Sullivan JL. Why high levels of virus-specific CTL persist in HIV1-infected individuals. Res Immunol. 1989 Jan; 140(1):92-5; discussion 118-9.
|
|
|
|
|
97.
|
Sullivan JL, Woda BA. X-linked lymphoproliferative syndrome. Immunodefic Rev. 1989; 1(4):325-47.
|
|
|
|
|
98.
|
Hesselton RM, Yang WC, Medveczky P, Sullivan JL. Pathogenesis of Herpesvirus sylvilagus infection in cottontail rabbits. Am J Pathol. 1988 Dec; 133(3):639-47.
|
|
|
|
|
99.
|
Sullivan JL. Epstein-Barr virus and lymphoproliferative disorders. Semin Hematol. 1988 Jul; 25(3):269-79.
|
|
|
|
|
100.
|
Brettler DB, Forsberg AD, Levine PH, Andrews CA, Baker S, Sullivan JL. Human immunodeficiency virus isolation studies and antibody testing. Household contacts and sexual partners of persons with hemophilia. Arch Intern Med. 1988 Jun; 148(6):1299-301.
|
|
|
|
|
101.
|
Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987 Dec 1; 139(11):3802-7.
|
|
|
|
|
102.
|
Andrews CA, Sullivan JL, Brettler DB, Brewster FE, Forsberg AD, Scesney S, Levine PH. Isolation of human immunodeficiency virus from hemophiliacs: correlation with clinical symptoms and immunologic abnormalities. J Pediatr. 1987 Nov; 111(5):672-7.
|
|
|
|
|
103.
|
Daum GS, Sullivan JL, Ansell J, Mulder C, Woda BA. Virus-associated hemophagocytic syndrome: identification of an immunoproliferative precursor lesion. Hum Pathol. 1987 Oct; 18(10):1071-4.
|
|
|
|
|
104.
|
Sullivan JL. Judicially-ordered involuntary treatment of the mentally ill. J Mo Bar. 1975 Jun; 31:254-8.
|
|
|
|
